心血管疾病中的药物遗传学：法国国家药物遗传学网络（RNPGx）的现状与实施建议

Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).

作者信息

Lamoureux Fabien, Duflot Thomas

机构信息

Service de pharmacologie, laboratoire de pharmacologie-toxicologie et pharmacogénétique, centre hospitalier universitaire, 76031 Rouen, France; Inserm unité 1096, pharmacologie des dysfonctionnements endothéliaux et myocardiques, faculté de médecine et de pharmacie, université de Rouen, 76000 Rouen, France.

出版信息

Therapie. 2017 Apr;72(2):257-267. doi: 10.1016/j.therap.2016.09.017. Epub 2017 Jan 30.

DOI:10.1016/j.therap.2016.09.017

PMID:28237404

Abstract

The use of genomic markers to predict drug response and effectiveness has the potential to improve healthcare by increasing drug efficacy and minimizing adverse effects. Polymorphisms associated with inter-individual variability in drug metabolism, transport, or pharmacodynamics of major cardiovascular drugs have been identified. These include single nucleotide polymorphisms (SNP) affecting clinical outcomes in patients receiving antiplatelet agents, oral anticoagulants and statins. Based on clinical evidence supporting genetic testing in the management of cardiovascular diseases using these drug classes, this short review presents clinical guidance regarding current pharmacogenetics implementation in routine medical practice.

摘要

使用基因组标记物预测药物反应和有效性，有可能通过提高药物疗效和将不良反应降至最低来改善医疗保健。已确定与主要心血管药物的药物代谢、转运或药效学个体间差异相关的多态性。这些包括影响接受抗血小板药物、口服抗凝剂和他汀类药物治疗患者临床结局的单核苷酸多态性（SNP）。基于支持在心血管疾病管理中使用这些药物类别进行基因检测的临床证据，本简短综述提供了关于当前药物遗传学在常规医疗实践中实施的临床指导。